Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) with AI Score 45/100 (Weak). Shanghai Pharmaceuticals Holding Co. , Ltd. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) Healthcare & Pipeline Overview
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the Chinese pharmaceutical market, with a diversified portfolio spanning drug manufacturing, distribution, and retail. The company's extensive network of retail pharmacies and focus on key therapeutic areas position it competitively within China's growing healthcare sector, supported by a beta of 0.33.
Investment Thesis
Shanghai Pharmaceuticals presents a compelling investment case based on its established market position and diversified operations within China's expanding healthcare sector. With a P/E ratio of 11.36 and a dividend yield of 2.37%, the company offers a blend of value and income. Growth catalysts include the increasing demand for healthcare products and services in China, driven by an aging population and rising income levels. The company's extensive distribution network and retail presence provide a competitive edge. However, investors may want to evaluate the risks associated with regulatory changes in the pharmaceutical industry and the competitive pressures from both domestic and international players. The company's profit margin of 2.0% and gross margin of 10.6% indicate areas for potential improvement in operational efficiency.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $8.46 billion, reflecting its significant presence in the Chinese pharmaceutical market.
- P/E ratio of 11.36, suggesting a potentially undervalued investment relative to its earnings.
- Dividend yield of 2.37%, offering a steady income stream for investors.
- Gross margin of 10.6%, indicating the profitability of its core business activities.
- Beta of 0.33, suggesting lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Extensive distribution network and retail presence in China.
- Diversified product portfolio spanning various therapeutic areas.
- Strong brand recognition and reputation.
- Established relationships with hospitals and healthcare providers.
Weaknesses
- Relatively low profit margin compared to global peers.
- Dependence on the Chinese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited presence in international markets.
Catalysts
- Ongoing: Expansion of the online pharmacy business to capture a larger market share.
- Ongoing: Increased investment in R&D to develop innovative drugs and expand the product portfolio.
- Upcoming: Potential strategic partnerships and acquisitions to expand market reach and access new technologies.
- Ongoing: Development of value-added services to generate additional revenue streams and enhance customer loyalty.
- Ongoing: Government policies supporting the growth of the pharmaceutical industry in China.
Risks
- Potential: Increasing competition from domestic and international players in the Chinese pharmaceutical market.
- Potential: Pricing pressures from generic drugs and government regulations.
- Potential: Regulatory changes and compliance requirements that could impact operations and profitability.
- Potential: Economic slowdown in China that could reduce demand for pharmaceutical products.
- Ongoing: Risks associated with operating in the OTC market, including limited liquidity and disclosure.
Growth Opportunities
- Expansion of Online Pharmacy Business: Shanghai Pharmaceuticals can capitalize on the growing trend of online pharmacies in China. By expanding its online platform and offering a wider range of products and services, the company can reach a larger customer base and increase its market share. The e-commerce market in China is expected to continue its double-digit growth, providing a significant opportunity for the company. Timeline: Ongoing.
- Increased Focus on R&D and Innovative Drugs: Investing in research and development to develop innovative drugs can drive future growth. The company can focus on developing drugs for therapeutic areas with unmet needs, such as oncology and CNS disorders. This will not only enhance its product portfolio but also improve its profitability. The Chinese government is also encouraging innovation in the pharmaceutical industry, providing further support for R&D activities. Timeline: Ongoing.
- Expansion into Rural Markets: Expanding its retail pharmacy network into rural areas can provide access to a large untapped market. The healthcare needs in rural areas are often underserved, presenting a significant opportunity for growth. The company can leverage its existing distribution network to efficiently serve these markets. Timeline: Upcoming, within 2-3 years.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller players can help expand its product portfolio and market reach. This can also provide access to new technologies and expertise. The pharmaceutical industry is consolidating globally, and Shanghai Pharmaceuticals can benefit from this trend. Timeline: Ongoing.
- Development of Value-Added Services: The company can further develop its value-added services, such as consulting, asset management, clinical trials, medical aid, and physician and patient education. These services can generate additional revenue streams and enhance customer loyalty. The demand for these services is increasing as healthcare becomes more complex and patients become more informed. Timeline: Ongoing.
Opportunities
- Expansion into rural markets in China.
- Increased focus on R&D and innovative drugs.
- Strategic partnerships and acquisitions.
- Development of value-added services.
Threats
- Increasing competition from domestic and international players.
- Pricing pressures from generic drugs.
- Regulatory changes and compliance requirements.
- Economic slowdown in China.
Competitive Advantages
- Extensive distribution network and retail presence in China.
- Diversified product portfolio spanning various therapeutic areas.
- Strong brand recognition and reputation in the Chinese pharmaceutical market.
- Established relationships with hospitals and healthcare providers.
About SHPMF
Founded in 1994 and headquartered in Shanghai, Shanghai Pharmaceuticals Holding Co., Ltd. has evolved into a comprehensive pharmaceutical enterprise. As an investment holding company and a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., it is deeply rooted in the Chinese healthcare landscape. The company operates through four key segments: Production, Distribution, Retail, and Others. Its product offerings encompass a wide array of pharmaceuticals, including chemicals and biochemicals, traditional Chinese medicines, healthcare products, and medical devices. These products target various therapeutic areas such as oncology, cerebrocardiovascular diseases, central nervous system disorders, general infections, immunology, digestive and metabolic ailments, and respiratory conditions. Shanghai Pharmaceuticals provides approximately 700 drug varieties. Beyond manufacturing, the company offers extensive pharmaceutical distribution, warehousing, and logistics services. It also manages a network of approximately 2,000 retail chain pharmacies across 24 provinces, complemented by an online drug business. The company extends its services to consulting, asset management, clinical trials, medical aid, and physician and patient education, further solidifying its presence in the healthcare ecosystem.
What They Do
- Researches and develops pharmaceutical products.
- Manufactures a wide range of drugs, including chemicals, biochemicals, and traditional Chinese medicines.
- Distributes pharmaceutical products to hospitals, distributors, and retail pharmacies.
- Operates a network of approximately 2,000 retail chain pharmacies.
- Provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions.
- Engages in online drug business.
- Offers consulting services, asset management operations, and clinical trials.
- Provides medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals.
Business Model
- Manufacturing and selling pharmaceutical products.
- Providing pharmaceutical distribution and logistics services.
- Operating retail pharmacies and selling drugs directly to consumers.
- Offering value-added services such as consulting and clinical trials.
Industry Context
Shanghai Pharmaceuticals operates within the rapidly growing Chinese pharmaceutical market. The industry is characterized by increasing demand for healthcare products and services, driven by an aging population, rising income levels, and increasing health awareness. The company faces competition from both domestic players and international pharmaceutical giants. Key trends include the increasing adoption of generic drugs, the growing importance of online pharmacies, and the evolving regulatory landscape. The company's extensive distribution network and retail presence provide a competitive advantage in this dynamic market.
Key Customers
- Hospitals and healthcare providers.
- Pharmaceutical distributors.
- Retail pharmacies.
- Individual consumers.
Financials
Chart & Info
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) stock price: Price data unavailable
Latest News
-
New 52-Week Lows For Monday Morning
· Aug 5, 2019
-
Stocks That Set New 52-Week Lows Friday Morning
· Aug 2, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHPMF.
Price Targets
Wall Street price target analysis for SHPMF.
MoonshotScore
What does this score mean?
The MoonshotScore rates SHPMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Qiuhua Yang
CEO
Qiuhua Yang is the CEO of Shanghai Pharmaceuticals Holding Co., Ltd. Details regarding Yang's specific educational background and prior roles are not available in the provided data. As the CEO, Yang is responsible for leading the company's strategic direction, overseeing its operations, and managing its relationships with stakeholders. Yang's leadership is crucial for navigating the complex regulatory environment and competitive landscape of the Chinese pharmaceutical market.
Track Record: As CEO of Shanghai Pharmaceuticals, Qiuhua Yang manages a large workforce of 49,402 employees. Specific achievements and strategic decisions under Yang's leadership are not detailed in the provided data. However, the company's continued growth and expansion in the Chinese pharmaceutical market reflect Yang's ability to guide the company effectively. Further information is needed to fully assess Yang's track record.
SHPMF OTC Market Information
The OTC Other tier, where SHPMF trades, represents the lowest tier of the OTC market. Companies in this tier may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. This often indicates limited financial disclosure and potentially higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware that companies in this tier may have limited operating history or be in early stages of development.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low liquidity can make it difficult to exit the investment.
- Lack of regulatory oversight compared to major exchanges.
- Potential for price manipulation due to low trading volume.
- Higher risk of company failure or delisting.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the company's regulatory environment and compliance requirements.
- Evaluate the company's liquidity and trading volume.
- Consult with a financial advisor before investing.
- Subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
- Operates a large network of retail pharmacies.
- Involved in the research, development, and manufacturing of pharmaceutical products.
- Presence in the Chinese pharmaceutical market since 1994.
SHPMF Healthcare Stock FAQ
What does Shanghai Pharmaceuticals Holding Co., Ltd do?
Shanghai Pharmaceuticals Holding Co., Ltd. is a comprehensive pharmaceutical company operating across the value chain, from research and development to manufacturing, distribution, and retail. The company produces a wide range of pharmaceutical products, including chemicals, biochemicals, and traditional Chinese medicines, targeting various therapeutic areas. Its extensive distribution network and retail pharmacy chain provide a strong market presence in China, complemented by online drug sales and value-added services like consulting and clinical trials.
What do analysts say about SHPMF stock?
AI analysis is currently pending for SHPMF, so an analyst consensus is not available at this time. Key valuation metrics include a P/E ratio of 11.36 and a dividend yield of 2.37%. Growth considerations center on the company's ability to capitalize on the expanding Chinese healthcare market and its investments in R&D. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for SHPMF?
The main risks for Shanghai Pharmaceuticals include increasing competition in the Chinese pharmaceutical market, pricing pressures from generic drugs, and regulatory changes that could impact operations. As an OTC-listed company, SHPMF also faces risks associated with limited liquidity and disclosure. Investors should carefully consider these factors and conduct thorough due diligence before investing.
What are the key factors to evaluate for SHPMF?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) currently holds an AI score of 45/100, indicating low score. Key strength: Extensive distribution network and retail presence in China.. Primary risk to monitor: Potential: Increasing competition from domestic and international players in the Chinese pharmaceutical market.. This is not financial advice.
How frequently does SHPMF data refresh on this page?
SHPMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SHPMF's recent stock price performance?
Recent price movement in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Extensive distribution network and retail presence in China.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SHPMF overvalued or undervalued right now?
Determining whether Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SHPMF?
Before investing in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.